tisxell -generated bone grafts – a pre-clinical study
Post on 02-Feb-2016
41 Views
Preview:
DESCRIPTION
TRANSCRIPT
Dr Mark ChongNational University of Singapore
Dept of Obstetrics and Gynaecology
2nd most transplanted tissue• 1 million cases annually in US alone
Current treatment:• Autograft: Site morbidity• Allograft: Donor shortage, immune rejection
Solution: Tissue Engineering
Resorbable scaffolds + osteogenic cells
Mature in bioreactor TisXell System Note:
• Function of bone is primarily structural low hanging fruit
Mesencymal stem cells
(MSC)
Day 0 Day 14 Day 28
Increased cellular
proliferation
Increased mineralisationT
isXell
Day 0 Day 14 Day 28
Increased cellular
proliferation
Increased mineralisation
Increased viability
LiveDead
TisXell
TisXell
Created 7 mm defect Press-fit 8 mm graft
SS
S
S
S
S
TisXell stimulates bone formation• 5.7 x more mineralisation than static
TisXell generated bone grafts are highly efficacious• Rapid healing of fracture within 3 months vs
non-union
Minipig model Larger volume, anticipate issues of
vascularisation Introduce endothelial progenitor cells
(EPC) into cellular mix
Mesencymal stem cells
(MSC)
Endothelial Progenitor Cells (EPC)
TisXell supports co-culture of different cell types
MSCEPC
18 mm segmental defect in tibia Monitor over 12 months:
• X-ray, CT, angiography
1 mth
3 mth
fMSC-EPC
1 mth
MSC
MSC
1 mth
3 mth
fMSC-EPC
1 mth
6 pigs implanted with TisXell cultured TEBG
All pigs survived; no adverse reaction
Mineralisation and bridging evident at 3 mths in MSC group; 1 mth in fMSC-EPC group
Studies to continue for long-term safety data (12 months)
TisXell provides a controlled and conducive environment for generating TEBG implant
Potent osteo-stimulatory cues Efficacy demonstrated in rat model Potentially faster bone regeneration
and vascularisation in minipig model Preparatory work with clinicians for
Clinical Phase I trial
top related